Schizoaffective Disorder, Schizophrenia
Conditions
Keywords
clozapine, ECT, PANSS, schizoaffective disorder, schizophrenia, treatment
Brief summary
Electroconvulsive therapy (ECT) is one of the oldest neuromodulation treatments still used in psychiatry. Only case reports and open label non-randomized studies have been published of ECT in clozapine-resistant schizophrenia patients. The purpose of this trial is to study the efficacy and cognitive effects of add-on ECT treatment (10-course) in schizophrenia patients taking clozapine.
Interventions
DEVICEelectroconvulsive therapy
10-course, three times a week bilateral frontotemporal ECT
Sponsors
Niuvanniemi Hospital
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
SINGLE (Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 64 Years
Healthy volunteers
No
Inclusion criteria
* diagnosis of schizophrenia or schizoaffective disorder * treatment-resistant to clozapine * age 18 - 64 years * capacity and willingness to give informed consent
Exclusion criteria
* serious somatic illness * progressive neurological illness, recent brain damage or sequela of serious brain damage * ECT less than 3 months prior to this trial
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Positive and Negative Symptom Scale | 2 days | Positive and Negative Symptom Scale (PANSS) is assessed two days after ECT course |
Countries
Finland
Contacts
Primary ContactEila Tiihonen, MD, PhD
Backup ContactSoile Hyvärinen, MD
Outcome results
None listed